WASHINGTON--(BUSINESS WIRE)--Tomorrow, IVY and Immunomic Therapeutics, Inc. (ITI) will host Greg Simon, the Executive Director of the Biden Cancer Initiative, for a lively discussion on eradicating cancer. The conversation, moderated by Immunomic Therapeutics CEO, Dr. Bill Hearl, will explore lessons learned so far from the cancer moonshot initiative and share how the government, academia, non-profits and the private sector can best organize their resources to further cancer research.
Who: Greg Simon, Director, Biden Cancer Initiative at Biden Foundation and Immunomic Therapeutics, Inc. CEO Dr. Bill Hearl.
What: Discussion on How to Eradicate Cancer: Lessons Learned from the Cancer Moonshot Initiative
When: Wednesday, May 24, 2017, 7:00 p.m. EDT
Where: Morgan, Lewis and Bockius, 1111 Pennsylvania Ave, NW, Washington, D.C.
About The Biden Foundation
The Biden Foundation is an educational foundation dedicated to ensuring that everyone—no matter their income level, race, gender, age, or sexuality—is treated with dignity and gets a fair shot at achieving the American Dream. The Foundation will focus on the foreign and domestic policy work that Vice President and Dr. Biden have devoted their lives to, initially including the Cancer Initiative, ongoing work to support equality for all, changing the culture around domestic and sexual violence and Dr. Biden’s work to increase access to high quality affordable education in the United States and around the world.
Under Vice President Biden’s leadership, the White House Cancer Moonshot Task Force catalyzed novel, innovative and impactful collaborations among twenty government agencies, departments and White House offices and over seventy private sector collaborations designed to achieve a decades’ worth of progress in five years in the prevention, diagnosis and treatment of cancer. He helped lead the effort to pass the 21st Century Cures Act that provides $1.8 billion over seven years for the Cancer Moonshot’s scientific priorities.
Through the cancer initiative, Vice President Biden will continue his work to inject a sense of urgency into our cancer research enterprise and to reimagine how the government, academia, non-profits and the private sector can better organize their resources and systems to collaborate to take on cancer.
IVY: The Social University (IVY.com) is a lifelong community dedicated to learning, growing, and making an impact together. Our mission is to spark world changing collaborations, and start a 21st-century renaissance promoting human unity, progress, and fulfillment. We achieve this by introducing our members to the most transformative people, ideas, and experiences in the world.
Whether it’s in-person talks with world-class leaders including Lauren Bush Lauren, Ambassador Cameron Munter, GE Chairman Jack Welch, and Pulitzer Prize Winner Nicholas Kristof; cultural expeditions to Cuba and Iceland; or tickets to the Opera or Ballet — IVY provides its members a lifetime of learning. Over the past three years, the IVY community has grown to 20,000 inspiring members in seven cities across the nation including New York, D.C., Chicago, Los Angeles, San Francisco, Boston and Miami.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-vax for use in the prevention and treatment of allergic diseases, which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology to immuno-oncology. For information about ITI and LAMP Technology, visit www.immunomix.com or contact email@example.com.